Related references
Note: Only part of the references are listed.Targeted 5-HT1F Therapies for Migraine
Marta Vila-Pueyo
NEUROTHERAPEUTICS (2018)
Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
Eloisa Rubio-Beltran et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects
Ahmed N. Mahmoud et al.
BMJ OPEN (2018)
Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Bernice Kuca et al.
NEUROLOGY (2018)
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
David C. Goff et al.
CIRCULATION (2014)
5-HT1F Receptor Agonists: A New Treatment Option for Migraine Attacks?
Lars Neeb et al.
NEUROTHERAPEUTICS (2010)
The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity
EJC Dunkley et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2003)
Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment:: a meta-analysis of 53 trials
MD Ferrari et al.
LANCET (2001)
Share Paper
